Skip to main content

Smither John W

In the past year, 2 open-market sale filings worth $75.4K and no purchases.

Current role at each company

Show 1 more company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$75.4K
2 filings
Net
−$75.4K
Bought minus sold
Companies
2
With open-market trades

Trades

Every Form 4 that lists Smither John W as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

NAMS NewAmsterdam Pharma Co N.V.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 9, 2026 (view filing)4:30 PM ETSep 45 daysSmither John WDirectorSSale−1.60K$25.32−$40.5K−15.4%8.76K after

GNLX GENELUX Corp

Director4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 14, 2023 (view filing)Sep 131 daySmither John WDirectorSSale−900$20.78−$18.7K−11.5%6.92K after
Jun 7, 2024 (view filing)May 299 daysLateSmither John WDirectorPPurchase+6.25K––+90.3%13.2K after
Jun 7, 2024 (view filing)May 299 daysLateSmither John WDirectorPPurchase+6.25K–––6.25K afterDerivative
Jul 2, 2026 (view filing)4:35 PM ETJul 11 daySmither John WDirectorSSale−12.0K$2.91−$34.9K−11.6%91.4K after